Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.
about
Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro.Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse heartsActivation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone.Drug-induced mitochondrial dysfunction and cardiotoxicity.Vascular endothelial growth factor-A signaling in bone marrow-derived endothelial progenitor cells exposed to hypoxic stressExposure to rosiglitazone, a PPAR-γ agonist, in late gestation reduces the abundance of factors regulating cardiac metabolism and cardiomyocyte size in the sheep fetus.Diabetes and bone health: latest evidence and clinical implications.Identification of Bexarotene as a PPARγ Antagonist with HDX.Pharmacologic targeting of sirtuin and PPAR signaling improves longevity and mitochondrial physiology in respiratory chain complex I mutant Caenorhabditis elegans.Autologous fat transplants to deliver glitazone and adiponectin for vasculoprotection.Pioglitazone increases PGC1-α signaling within chronically ischemic myocardium.De novo fatty acid synthesis by Schwann cells is essential for peripheral nervous system myelination.Toxicoproteomics in human health and disease: an update.Hypoglycemic and hypotensive activity of a root extract of Smilax aristolochiifolia, standardized on N-trans-feruloyl-tyramine.Pioglitazone Induces Cardiomyocyte Apoptosis and Inhibits Cardiomyocyte Hypertrophy Via VEGFR-2 Signaling Pathway
P2860
Q30826981-2FC016B7-E87B-480A-AEAC-E90179C3FFE2Q34569388-48C27728-36BF-40F6-835D-ECE81C7F40F5Q35070472-307DF24F-383C-458E-BCB3-C6B09221DD3EQ35189862-D5CFA7F6-A660-4BC2-B298-953E7645AC9BQ36339445-8C8D75EF-B197-444A-9CC6-298CC98009F4Q37345998-B64A4D34-5E07-461F-B3CF-B0A9272E064FQ37629364-52D7BB9C-1A20-42B6-AACA-20C3DE773929Q37698523-408BB3D8-0E12-45AF-B728-EE907F30C2AAQ38441741-4E3CB29B-BFE4-4D13-BE79-ADC3C2C12F01Q39032373-83F0A3AE-6CD8-4269-A54E-0ED63330D0DAQ47779172-BB1955AD-C2B7-4ECC-9EE9-CC12265A3CDFQ48056508-3E4AB47B-8C8F-43B3-8219-5DF87DBCC5BCQ50056315-2A57F309-355D-438A-B894-C3AD1106ED86Q51344755-07B92126-57E2-49D4-A9F5-FCC9C147D577Q51806055-4D541DF9-F75E-40D0-A837-4B260ADAE72CQ58804870-49B61FBC-877B-4AA1-8867-7C24A627F357
P2860
Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Chemical proteomics-based anal ...... potential for cardiotoxicity.
@ast
Chemical proteomics-based anal ...... potential for cardiotoxicity.
@en
type
label
Chemical proteomics-based anal ...... potential for cardiotoxicity.
@ast
Chemical proteomics-based anal ...... potential for cardiotoxicity.
@en
prefLabel
Chemical proteomics-based anal ...... potential for cardiotoxicity.
@ast
Chemical proteomics-based anal ...... potential for cardiotoxicity.
@en
P2093
P2860
P356
P1476
Chemical proteomics-based anal ...... g potential for cardiotoxicity
@en
P2093
Andrew S Greene
Brian R Hoffmann
Daniel S Sem
P2860
P304
P356
10.1021/JM301204R
P407
P577
2012-09-28T00:00:00Z